0.62
+0.03(+5.11%)
Currency In USD
| Previous Close | 0.59 |
| Open | 0.56 |
| Day High | 0.58 |
| Day Low | 0.56 |
| 52-Week High | 8.72 |
| 52-Week Low | 0.46 |
| Volume | 486,417 |
| Average Volume | 21.28M |
| Market Cap | 8.91M |
| PE | 1.14 |
| EPS | 0.51 |
| Moving Average 50 Days | 0.84 |
| Moving Average 200 Days | 1.37 |
| Change | -0.01 |
If you invested $1000 in Scienture Holdings, Inc. (SCNX) since IPO date, it would be worth $82.43 as of November 18, 2025 at a share price of $0.617. Whereas If you bought $1000 worth of Scienture Holdings, Inc. (SCNX) shares 1 year ago, it would be worth $82.43 as of November 18, 2025 at a share price of $0.617.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans
GlobeNewswire Inc.
Nov 04, 2025 1:05 PM GMT
Expanded Coverage Reaches Over 100 Million Covered Lives Nationwide COMMACK, NY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on pro
SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)
GlobeNewswire Inc.
Oct 23, 2025 12:05 PM GMT
Company launches multi-channel promotional campaign to drive market adoption U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli™ as the first FDA-approved ready-to-use oral suspension COMMA
SCIENTURE’S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers
GlobeNewswire Inc.
Oct 16, 2025 1:00 PM GMT
Novel oral suspension addresses critical patient safety needs for hypertension treatment for patients unable to swallow tablets U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli™ as the fi